SG-3-00802 shows single agent activity and has potential to improve responses in patients resistant to approved immunotherapies with broad clinical development potential in earlier lines of therapy
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data demonstrating that the Company’s CXCR3-positive allosteric modulator, SG-3-00802, can reverse resistance to anti-programmed death protein-1 (PD-1) therapy, illustrating that the microbiome directly interacts with the human immune system to enhance immunity and impact antitumor activity. The data (E-Poster #569) were presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, held virtually and in Washington, D.C. November 10-14.
“We are encouraged by Second Genome’s growing body of preclinical data demonstrating that SG-3-00802’s differentiated mechanism of action has the potential to effectively target the tumor microenvironment and improve responses in combination with existing immunotherapies, such as checkpoint inhibitors and cytokines,” said Karim Dabbagh, Ph.D., Chief Executive Officer at Second Genome. “At SITC, we presented new data showing SG-3-00802 potently enhances CXCR3 ligand-induced cell migration, a critical effector cell recruitment mechanism for anti-tumor immunity. We look forward to further advancing our program with an IND submission expected in 2022.”
The poster presentation will be available for on-demand viewing on the SITC website through January 9, 2022, and it will also be made available on the Company’s website at https://www.secondgenome.com/news/events.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.